Drug Profile


Alternative Names: Kyprolis; ONO-7057; PR-171

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Proteolix
  • Developer Dana-Farber Cancer Institute; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Mantle-cell lymphoma; Prostate cancer; Renal cell carcinoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Acute lymphoblastic leukaemia; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Small cell lung cancer; Solid tumours
  • Phase I Leukaemia; Lymphoid leukaemia
  • No development reported Systemic lupus erythematosus

Most Recent Events

  • 15 Mar 2017 Onyx Therapeutics suspends enrolment in a phase Ib trial for Multiple myeloma (Combination therapy) in USA (NCT02335983)
  • 28 Feb 2017 Interim adverse events and efficacy data from the phase III ENDEAVOR trial in Multiple myeloma released by Amgen
  • 14 Feb 2017 Onyx Pharmaceuticals initiates enrolment in the phase II KIWI trial in Multiple myeloma (Newly diagnosed, Combination therapy, Induction and Consolidation therapy) in New Zealand (ACTRN12615000188538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top